Table 3 Base-case cost-effectiveness analysis
Strategy | Cost (US$) | DALYs | Incremental cost | Incremental DALYs averted | ICER |
|---|---|---|---|---|---|
No treatment | 0.00 | 17.60 | 0.00 | 0.00 | 0.00 |
AL | 165.42 | 4.47 | 165.42 | 13.13 | Extendedly dominated |
DhP | 166.22 | 4.22 | 0.80 | 0.25 | 12.40 |
Strategy | Cost (US$) | DALYs | Incremental cost | Incremental DALYs averted | ICER |
|---|---|---|---|---|---|
No treatment | 0.00 | 17.60 | 0.00 | 0.00 | 0.00 |
AL | 165.42 | 4.47 | 165.42 | 13.13 | Extendedly dominated |
DhP | 166.22 | 4.22 | 0.80 | 0.25 | 12.40 |